Antibody drug conjugates (ADCs) present a promising solution. These ‘magic bullets’ deliver treatment that is both highly targeted and highly potent, seeking out and attacking cancerous cells throughout the body, while avoiding harm to healthy cells.

Because of their inherent complexity, ADCs can take some time to gain approval and reach the market. By working with an experienced and dedicated partner, you can accelerate the delivery of these transformative molecules to patients.

At Sterling, we combine our expertise in containment with the specialised focus and experience of our dedicated bioconjugation team to provide comprehensive solutions for ADC discovery and development, supported by robust technical services.

свернуть